Related Experiment Video
Updated: Feb 9, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with
1Institute for Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz 4132, Switzerland.
Abstract:
Over 800 G-protein-coupled receptors (GPCRs) are encoded by the human genome and many are overexpressed in tumors. GPCRs are triggered by ligand molecules outside the cell and activate internal signal transduction pathways driving cellular responses. The receptor signals are desensitized by receptor internalization and this mechanism can be exploited for the specific delivery of ligand-linked drug molecules directly into cells. Detailed expression analysis in cancer tissue can inform the design of GPCR-ligand decorated drug carriers for active tumor cell targeting. The active targeting process utilizes ligand receptor interactions leading to binding and in most cases internalization of the ligand-attached drug carrier resulting in effective targeting of cancer cells. In this report public microarray data from the Gene Expression Omnibus (GEO) repository was used to identify overexpressed GPCRs in prostate and breast cancer tissues. The analyzed data confirmed previously known cancer receptor associations and identified novel candidates for potential active targeting. Prioritization of the identified targeting receptors is also presented based on high expression levels and frequencies in cancer samples but low expression in healthy tissue. Finally, some selected examples were used in ligand docking studies to assess the feasibility for chemical conjugation to drug nanocarriers without interference of receptor binding and activation. The presented data demonstrate a large untapped potential to improve efficacy and safety of current and future anti-cancer compounds through active targeting of GPCRs on cancer cells.
Insights
This study identifies overexpressed G-protein-coupled receptors (GPCRs) in prostate and breast cancers for targeted drug delivery. These findings pave the way for more effective and safer cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Over 800 G-protein-coupled receptors (GPCRs) exist, with many overexpressed in tumors.
- GPCRs mediate cellular responses upon ligand binding and are internalized for signal desensitization.
- Receptor internalization offers a mechanism for targeted drug delivery into cancer cells.
Purpose of the Study:
- To identify overexpressed GPCRs in prostate and breast cancer tissues for active tumor cell targeting.
- To prioritize GPCR candidates for drug carrier design based on expression profiles.
- To assess the feasibility of conjugating ligands to nanocarriers for GPCR targeting.
Main Methods:
- Analysis of public microarray data from the Gene Expression Omnibus (GEO) repository.
- Identification and prioritization of overexpressed GPCRs in cancer versus healthy tissues.
- Ligand docking studies for assessing chemical conjugation feasibility.
Main Results:
- Confirmed known cancer-associated GPCRs and identified novel candidates for active targeting.
- Prioritized GPCRs based on high cancer expression and low healthy tissue expression.
- Demonstrated feasibility of ligand conjugation to nanocarriers without compromising receptor binding.
Conclusions:
- Detailed GPCR expression analysis in cancer informs the design of targeted drug carriers.
- Active targeting of GPCRs presents a significant opportunity to enhance anti-cancer compound efficacy and safety.
- This approach holds untapped potential for improving current and future cancer treatments.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
GPCRs Regulate Adenylyl Cylase Activity
Design Example: Setting a Curve Using Design Data
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

